Does the media refer more to PRME or CRBU?

In the previous week, Caribou Biosciences had 1 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Caribou Biosciences and 3 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.37 beat Caribou Biosciences' score of 0.14 indicating that Prime Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MDXG or CRBU?

In the previous week, Caribou Biosciences had 3 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.54 beat Caribou Biosciences' score of 0.14 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ALT or CRBU?

In the previous week, Caribou Biosciences had 3 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for Altimmune. Caribou Biosciences' average media sentiment score of 0.14 beat Altimmune's score of -0.71 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, VALN or CRBU?

Valneva has higher revenue and earnings than Caribou Biosciences. Valneva is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Valneva $197.56M 3.15 -$130.33M -$2.11 N/A Caribou Biosciences $11.16M 12.49 -$148.12M -$1.08 N/A

Is VALN or CRBU more profitable?

Valneva has a net margin of -110.33% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Caribou Biosciences -1,030.42% -89.11% -62.47%

Does the media favor VALN or CRBU?

In the previous week, Caribou Biosciences had 3 more articles in the media than Valneva. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for Valneva. Valneva's average media sentiment score of 0.45 beat Caribou Biosciences' score of 0.14 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CRBU or SVA?

Sinovac Biotech has higher revenue and earnings than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caribou Biosciences $11.16M 12.49 -$148.12M -$1.08 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Caribou Biosciences (CRBU) Competitors

$1.30 -0.01 (-0.76%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.34 +0.03 (+2.69%)

As of 09/18/2026 07:30 PM Eastern

Compare

CRBU vs. PRME, MDXG, ALT, VALN, and SVA

Should you buy Caribou Biosciences stock or one of its competitors? Caribou Biosciences's main competitors and comparable companies include Prime Medicine (PRME), MiMedx Group (MDXG), Altimmune (ALT), Valneva (VALN), and Sinovac Biotech (SVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Caribou Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Caribou Biosciences has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	122.23	-$201.14M	-$1.06	N/A
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A

Prime Medicine has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market.

Prime Medicine currently has a consensus target price of $7.47, suggesting a potential upside of 139.49%. Caribou Biosciences has a consensus target price of $7.75, suggesting a potential upside of 496.15%. Given Caribou Biosciences' higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Caribou Biosciences has a net margin of -1,030.42% compared to Prime Medicine's net margin of -4,613.11%. Caribou Biosciences' return on equity of -89.11% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,613.11%	-188.27%	-59.11%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

In the previous week, Caribou Biosciences had 1 more articles in the media than Prime Medicine. MarketBeat recorded 4 mentions for Caribou Biosciences and 3 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.37 beat Caribou Biosciences' score of 0.14 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Prime Medicine and Caribou Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to MiMedx Group?

MiMedx Group (NASDAQ:MDXG) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

MiMedx Group has a net margin of 1.76% compared to Caribou Biosciences' net margin of -1,030.42%. MiMedx Group's return on equity of 12.09% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiMedx Group	1.76%	12.09%	9.22%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

MiMedx Group has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

In the previous week, Caribou Biosciences had 3 more articles in the media than MiMedx Group. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.54 beat Caribou Biosciences' score of 0.14 indicating that MiMedx Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiMedx Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Caribou Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.2% of MiMedx Group shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 2.5% of MiMedx Group shares are owned by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiMedx Group	$418.63M	1.66	$48.58M	$0.04	119.25
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A

MiMedx Group currently has a consensus price target of $8.57, suggesting a potential upside of 79.69%. Caribou Biosciences has a consensus price target of $7.75, suggesting a potential upside of 496.15%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

MiMedx Group beats Caribou Biosciences on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Altimmune has higher earnings, but lower revenue than Caribou Biosciences. Altimmune is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	15,804.75	-$88.09M	-$0.78	N/A
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A

Altimmune has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Caribou Biosciences has a net margin of -1,030.42% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-31.41%	-26.96%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Altimmune currently has a consensus price target of $14.33, indicating a potential upside of 341.03%. Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 496.15%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Caribou Biosciences had 3 more articles in the media than Altimmune. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for Altimmune. Caribou Biosciences' average media sentiment score of 0.14 beat Altimmune's score of -0.71 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Caribou Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.1% of Altimmune shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Caribou Biosciences beats Altimmune on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Valneva?

Valneva (NASDAQ:VALN) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

In the previous week, Caribou Biosciences had 3 more articles in the media than Valneva. MarketBeat recorded 4 mentions for Caribou Biosciences and 1 mentions for Valneva. Valneva's average media sentiment score of 0.45 beat Caribou Biosciences' score of 0.14 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valneva has higher revenue and earnings than Caribou Biosciences. Valneva is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.15	-$130.33M	-$2.11	N/A
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A

Valneva currently has a consensus price target of $9.30, indicating a potential upside of 41.77%. Caribou Biosciences has a consensus price target of $7.75, indicating a potential upside of 496.15%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Valneva has a net margin of -110.33% compared to Caribou Biosciences' net margin of -1,030.42%. Caribou Biosciences' return on equity of -89.11% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

Summary

Caribou Biosciences beats Valneva on 11 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Sinovac Biotech?

Caribou Biosciences (NASDAQ:CRBU) and Sinovac Biotech (NASDAQ:SVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.

Sinovac Biotech has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Sinovac Biotech's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Sinovac Biotech	N/A	N/A	N/A

Caribou Biosciences has a beta of 2.28, indicating that its stock price is 128% more volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Caribou Biosciences had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 4 mentions for Caribou Biosciences and 0 mentions for Sinovac Biotech. Caribou Biosciences' average media sentiment score of 0.14 beat Sinovac Biotech's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Caribou Biosciences	Neutral
Sinovac Biotech	Neutral

Caribou Biosciences currently has a consensus target price of $7.75, suggesting a potential upside of 496.15%. Sinovac Biotech has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Given Caribou Biosciences' higher possible upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Sinovac Biotech has higher revenue and earnings than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	12.49	-$148.12M	-$1.08	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Caribou Biosciences beats Sinovac Biotech on 8 of the 15 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$139.37M	$3.88B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-1.20	14.23	275.49	25.40
Price / Sales	12.49	1,440.84	644.44	86.30
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	0.99	15.45	10.46	6.33
Net Income	-$148.12M	-$22.86M	$3.49B	$358.33M
7 Day Performance	2.36%	-1.21%	0.59%	1.12%
1 Month Performance	-19.25%	-3.29%	-1.74%	-2.39%
1 Year Performance	-23.08%	37.74%	18.13%	5.35%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	2.092 of 5 stars	$1.30 -0.8%	$7.75 +496.2%	-23.1%	$139.37M	$11.16M	N/A	97	News Coverage Analyst Downgrade
PRME Prime Medicine	2.5753 of 5 stars	$3.70 flat	$7.47 +102.0%	-36.2%	$671.09M	$4.63M	N/A	N/A	News Coverage
MDXG MiMedx Group	2.8671 of 5 stars	$4.57 flat	$8.57 +87.6%	-32.1%	$666.12M	$418.63M	114.28	870	Analyst Forecast
ALT Altimmune	2.0907 of 5 stars	$3.42 flat	$14.33 +319.1%	-14.0%	$665.25M	$40K	N/A	50
VALN Valneva	1.7853 of 5 stars	$6.89 flat	$9.30 +35.0%	-35.6%	$653.76M	$197.56M	N/A	700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. PRME, MDXG, ALT, VALN, and SVA

How does Caribou Biosciences compare to Prime Medicine?

Summary

How does Caribou Biosciences compare to MiMedx Group?

Summary

How does Caribou Biosciences compare to Altimmune?

Summary

How does Caribou Biosciences compare to Valneva?

Summary

How does Caribou Biosciences compare to Sinovac Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. PRME, MDXG, ALT, VALN, and SVA

How does Caribou Biosciences compare to Prime Medicine?

Which has stronger earnings & valuation, PRME or CRBU?

Which has more volatility and risk, PRME or CRBU?

Do analysts prefer PRME or CRBU?

Is PRME or CRBU more profitable?

Does the media refer more to PRME or CRBU?

Do institutionals & insiders hold more shares of PRME or CRBU?

Summary

How does Caribou Biosciences compare to MiMedx Group?

Is MDXG or CRBU more profitable?

Which has more volatility and risk, MDXG or CRBU?

Does the media favor MDXG or CRBU?

Do institutionals and insiders hold more shares of MDXG or CRBU?

Which has stronger valuation and earnings, MDXG or CRBU?

Do analysts recommend MDXG or CRBU?

Summary

How does Caribou Biosciences compare to Altimmune?

Which has stronger earnings and valuation, ALT or CRBU?

Which has more volatility and risk, ALT or CRBU?

Is ALT or CRBU more profitable?

Do analysts recommend ALT or CRBU?

Does the media refer more to ALT or CRBU?

Do institutionals and insiders have more ownership in ALT or CRBU?

Summary

How does Caribou Biosciences compare to Valneva?

Does the media favor VALN or CRBU?

Which has more volatility and risk, VALN or CRBU?

Do institutionals & insiders believe in VALN or CRBU?

Which has better earnings & valuation, VALN or CRBU?

Do analysts prefer VALN or CRBU?

Is VALN or CRBU more profitable?

Summary

How does Caribou Biosciences compare to Sinovac Biotech?

Is CRBU or SVA more profitable?

Which has more risk & volatility, CRBU or SVA?

Does the media prefer CRBU or SVA?

Do analysts rate CRBU or SVA?

Which has stronger valuation & earnings, CRBU or SVA?

Do institutionals and insiders believe in CRBU or SVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools